Zydus Cadila becomes second Indian pharma with US IND for GK activator in diabetes
This article was originally published in Scrip
Executive Summary
Zydus Cadila, one of India’s leading healthcare companies announced that it has received an IND approval from the US FDA for ZYGK1, an orally administered small molecule glucokinase activator for Type 2 diabetes. The move reinforces Zydus' transition from its heavy dependence on generics to its ambitions as a research-led company. It also makes Zydus the second Indian company exploring the glucokinase activation space, alongside Advinus.
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.